SNS-314
Potent and Selective Inhibitor of Aurora Kinases A, B, and C for Advanced Solid Tumors
SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death. See the SNS-314 mechanism of action.
SNS-314 Presentations
A Phase 1 Trial of SNS-314, a Novel and Selective Pan-Aurora Kinase Inhibitor, in Advanced Solid Tumor PatientsAmerican Society of Clinical Oncology 2009 Annual Meeting
Orlando, FL
May 30th, 2009
A Phase 1 Trial of SNS-314, A Novel and Selective Pan-Aurora Kinase Inhibitor, in Advanced Solid Tumor Patients20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics"
Geneva, Switzerland
October 23rd, 2008
SNS-314, A POTENT INHIBITOR OF AURORA KINASES, HAS PRECLINICAL ANTI-TUMOR ACTIVITY AND INDUCES APOPTOSIS2008 AACR Annual Meeting
San Diego, CA
April 16th, 2008
Learn more about completed SNS-314 Phase 1 in clinical trials
Get general information about clinical studies, and learn about Sunesis investigational drugs currently in clinical trial.
Strategic alliances allow us to expand our development and marketing efforts.
Copyright © Sunesis Pharmaceuticals, Inc. 2007. All Rights Reserved.